ATE527357T1 - Agonistischer antikörper gegen proteintyrosinkinase sal-s1 - Google Patents

Agonistischer antikörper gegen proteintyrosinkinase sal-s1

Info

Publication number
ATE527357T1
ATE527357T1 AT08021130T AT08021130T ATE527357T1 AT E527357 T1 ATE527357 T1 AT E527357T1 AT 08021130 T AT08021130 T AT 08021130T AT 08021130 T AT08021130 T AT 08021130T AT E527357 T1 ATE527357 T1 AT E527357T1
Authority
AT
Austria
Prior art keywords
tyrosine kinase
protein tyrosine
sal
receptor
antibody against
Prior art date
Application number
AT08021130T
Other languages
English (en)
Inventor
Brian D Bennett
David Goeddel
James M Lee
William Matthews
Siao Ping Tsai
William I Wood
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE527357T1 publication Critical patent/ATE527357T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Enzymes And Modification Thereof (AREA)
AT08021130T 1994-04-04 1995-04-04 Agonistischer antikörper gegen proteintyrosinkinase sal-s1 ATE527357T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/222,616 US5635177A (en) 1992-01-22 1994-04-04 Protein tyrosine kinase agonist antibodies

Publications (1)

Publication Number Publication Date
ATE527357T1 true ATE527357T1 (de) 2011-10-15

Family

ID=22832973

Family Applications (2)

Application Number Title Priority Date Filing Date
AT95916208T ATE489402T1 (de) 1994-04-04 1995-04-04 Fusionsprotein dass bptk7 enthält
AT08021130T ATE527357T1 (de) 1994-04-04 1995-04-04 Agonistischer antikörper gegen proteintyrosinkinase sal-s1

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT95916208T ATE489402T1 (de) 1994-04-04 1995-04-04 Fusionsprotein dass bptk7 enthält

Country Status (11)

Country Link
US (1) US5635177A (de)
EP (2) EP0804572B1 (de)
JP (2) JPH09511644A (de)
AT (2) ATE489402T1 (de)
CA (1) CA2185656C (de)
DE (1) DE69536123D1 (de)
DK (2) DK0804572T3 (de)
ES (2) ES2355952T3 (de)
MX (1) MX9604316A (de)
PT (2) PT2067790E (de)
WO (1) WO1995027061A1 (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6331302B1 (en) 1992-01-22 2001-12-18 Genentech, Inc. Protein tyrosine kinase agonist antibodies
US6824777B1 (en) 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
US6107046A (en) * 1992-10-09 2000-08-22 Orion Corporation Antibodies to Flt4, a receptor tyrosine kinase and uses thereof
US6992175B1 (en) 1994-04-15 2006-01-31 Amgen Inc. Nucleic acids encoding Eph-like receptor tyrosine kinases
WO1995028484A1 (en) * 1994-04-15 1995-10-26 Amgen Inc. Hek5, hek7, hek8, hek11, new eph-like receptor protein tyrosine kinases
US6326469B1 (en) 1994-04-22 2001-12-04 Sugen, Inc. Megakaryocytic protein tyrosine kinases
US6506578B1 (en) * 1994-04-22 2003-01-14 Sugen, Inc. Nucelotide encoding megakaryocytic protein tyrosine kinases
US5864020A (en) * 1994-07-20 1999-01-26 Genentech, Inc. HTK ligand
US6143714A (en) * 1994-10-24 2000-11-07 Regeneron Pharmaceuticals, Inc. Methods of using hepatocyte growth factor to promote survival, growth and differentiation of motor neurons
WO2002060950A2 (en) 1994-11-14 2002-08-08 Ludwig Institute For Cancer Research Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy
US6541604B1 (en) 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
US20050019325A1 (en) * 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
US20060205660A1 (en) * 1996-06-20 2006-09-14 Sauvage Frederic D OB protein-immunoglobulin chimeras
EP0912734B1 (de) 1996-07-12 2010-11-03 Genentech, Inc. Chimärische heteromultimerische adhesine
WO1998002541A1 (en) 1996-07-12 1998-01-22 Genentech, Inc. Gamma-heregulin
JPH10234372A (ja) * 1997-02-27 1998-09-08 Boehringer Mannheim Corp キメラ受容体を有する細胞とその作成方法、並びに その利用
ATE359367T1 (de) * 1997-04-15 2007-05-15 Wellcome Trust Ltd As Trustee Ldl-rezeptor
AUPO754997A0 (en) * 1997-06-25 1997-07-17 Leukaemia Foundation Of Queensland, The Receptor-ligand system and assay therefor
US5980893A (en) * 1997-07-17 1999-11-09 Beth Israel Deaconess Medical Center, Inc. Agonist murine monoclonal antibody as a stimulant for megakaryocytopoiesis
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
US20030049676A1 (en) 1997-09-17 2003-03-13 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7169906B2 (en) * 1997-09-17 2007-01-30 Genentech, Inc. PRO211 polypeptides
US6974689B1 (en) * 1997-09-18 2005-12-13 Genentech, Inc. Nucleic acid encoding PRO211 polypeptides
US6312941B1 (en) 1997-11-26 2001-11-06 The Regents Of The University Of Michigan Compositions and methods for identifying signaling pathway agonists and antagonists
US6887674B1 (en) 1998-04-13 2005-05-03 California Institute Of Technology Artery- and vein-specific proteins and uses therefor
US6864227B1 (en) 1998-04-13 2005-03-08 California Institute Of Technology Artery-and vein-specific proteins and uses therefor
FR2783325A1 (fr) * 1998-09-11 2000-03-17 Inst Nat Sante Rech Med Moyens pour le controle de la regulation negative d'une activation transmise par un rtk
CA2345276C (en) * 1998-10-09 2011-03-29 Ludwig Institute For Cancer Research Flt4 (vegfr-3) as a target for tumor imaging and anti-tumor therapy
WO2000030673A1 (en) * 1998-11-20 2000-06-02 Genentech, Inc. Uses for eph receptor antagonists and agonists to treat vascular disorders
EP1553414A1 (de) * 1999-04-13 2005-07-13 Medarex, Inc. Methoden zur Diagnose und Behandlung metastasierender Prostata-Tumore
CA2370237A1 (en) * 1999-04-13 2000-10-19 Northwest Biotherapeutics, Inc. Methods for the diagnosis and treatment of metastatic prostate tumors
US8084258B2 (en) * 1999-07-12 2011-12-27 University Of Basel Manipulation of tissue of organ type using the notch pathway
US7192698B1 (en) * 1999-08-17 2007-03-20 Purdue Research Foundation EphA2 as a diagnostic target for metastatic cancer
US6927203B1 (en) * 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
AU2002315253A1 (en) * 2001-03-16 2002-10-21 Bayer Aktiengesellschaft Regulation of human protein kinase-like protein
CN1555488A (zh) * 2001-07-12 2004-12-15 路德维格癌症研究院 淋巴管内皮细胞物质及方法
EP2075256A2 (de) 2002-01-14 2009-07-01 William Herman Gezielte Liganden
US20050152899A1 (en) * 2002-05-10 2005-07-14 Kinch Michael S. EphA2 agonistic monoclonal antibodies and methods of use thereof
ES2377720T3 (es) * 2002-05-10 2012-03-30 Purdue Research Foundation Anticuerpos monoclonales agon�?sticos epha2 y métodos de uso de los mismos.
US20040028685A1 (en) * 2002-05-10 2004-02-12 Kinch Michael S. EphA2 monoclonal antibodies and methods of use thereof
AU2002951409A0 (en) * 2002-09-16 2002-09-26 North Western Adelaide Health Services Methods for regulating cancer
EP2052713A3 (de) * 2003-01-13 2009-05-20 Macrogenics, Inc. Lösliche FcgammaR-Fusionsproteine und Verfahren zu deren Verwendung
US7381410B2 (en) * 2003-03-12 2008-06-03 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
JP2006521111A (ja) * 2003-03-12 2006-09-21 バスジーン セラピューティクス， インコーポレイテッド 血管形成及び腫瘍増殖阻害用ポリペプチド化合物及びその応用
JP2006524693A (ja) * 2003-04-11 2006-11-02 メディミューン，インコーポレーテッド ＥｐｈＡ２および非腫瘍性過増殖性細胞障害
AU2004230539A1 (en) * 2003-04-11 2004-10-28 Medimmune, Llc EphA2, hypoproliferative cell disorders and epithelial and endothelial reconstitution
US7977463B2 (en) * 2004-03-12 2011-07-12 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
CN102718867A (zh) 2004-03-12 2012-10-10 瓦斯基因治疗公司 结合ephb4、抑制血管发生和肿瘤生长的抗体
WO2006023420A2 (en) * 2004-08-16 2006-03-02 Medimmune, Inc. Integrin antagonists with enhanced antibody dependent cell-mediated cytotoxicity activity
US20060204512A1 (en) * 2004-09-23 2006-09-14 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
JP2008514925A (ja) * 2004-09-23 2008-05-08 バスジーン セラピューティクス， インコーポレイテッド 腫瘍を検出し且つ治療するための組成物及び方法
CA2623387A1 (en) * 2005-09-23 2007-04-05 Vasgene Therapeutics, Inc. Use of ephrinb2 directed agents for the treatment or prevention of viral infections
TWI391402B (zh) * 2006-01-05 2013-04-01 Genentech Inc 抗ｅｐｈｂ４抗體及使用該抗體之方法
SI1973950T1 (sl) 2006-01-05 2015-01-30 Genentech, Inc. Anti-EphB4 protitelesa in postopki njihove uporabe
WO2007146959A2 (en) * 2006-06-12 2007-12-21 Receptor Biologix Inc. Pan-cell surface receptor- specific therapeutics
EP2020419A1 (de) * 2007-07-31 2009-02-04 Bayer Schering Pharma Aktiengesellschaft Fragmente von Antikörpern gegen EPH-B4
US8975377B2 (en) * 2007-08-13 2015-03-10 Vasgene Therapeutics, Inc Cancer treatment using humanized antibodies that bind to EphB4
SMT202000088T1 (it) 2013-02-18 2020-03-13 Vegenics Pty Ltd Molecole leganti ligandi e relativi usi

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4444878A (en) 1981-12-21 1984-04-24 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0173494A3 (de) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimäre Rezeptoren durch Verbindung und Expression von DNS
US4745055A (en) 1985-05-07 1988-05-17 California Biotechnology Inc. Fused protein for enzyme immunoassay system
DE3751908T2 (de) 1986-07-07 1997-02-06 Centocor Inc Chimärisches Murine-Mensch-Immunoglobulin, spezifisch für tumorassoziertes 17-1A Antigen
NO873164L (no) 1986-07-30 1988-02-01 Teijin Ltd Muse-humane kimaere antistoffer.
IL84285A (en) 1986-10-27 1993-03-15 Int Genetic Engineering Chimeric antibody with specificity to human tumor antigen
GB8626412D0 (en) 1986-11-05 1986-12-03 Clark M R Antibodies
CA1339445C (en) 1986-11-12 1997-09-09 The General Hospital Corporation Recombinant hybrid immunoglobulin molecules and method of use
JP3739009B2 (ja) 1989-11-07 2006-01-25 俊雄 高橋 マウス抗体ｖ領域遺伝子断片およびその遺伝子断片を用いたキメラ抗体の調製方法
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9009549D0 (en) 1990-04-27 1990-06-20 Celltech Ltd Recombinant antibody and method
WO1992014748A1 (en) * 1991-02-22 1992-09-03 American Cyanamid Company Identification of a novel human receptor tyrosine kinase gene
AU3139493A (en) * 1991-11-15 1993-06-15 Trustees Of Princeton University, The Totipotent hematopoietic stem cell receptors and their ligands
CA2128722A1 (en) * 1992-01-22 1993-08-05 William I. Wood Novel protein tyrosine kinases
EP0730646A1 (de) * 1993-11-23 1996-09-11 Genentech, Inc. Rse, protein tyrosin kinasen

Also Published As

Publication number Publication date
ES2373130T3 (es) 2012-01-31
EP2067790A3 (de) 2010-12-01
PT804572E (pt) 2011-03-02
DK0804572T3 (da) 2011-03-07
ES2355952T3 (es) 2011-04-01
EP0804572B1 (de) 2010-11-24
MX9604316A (es) 1997-06-28
CA2185656C (en) 2011-07-19
DE69536123D1 (de) 2011-01-05
US5635177A (en) 1997-06-03
EP2067790B1 (de) 2011-10-05
DK2067790T3 (da) 2012-01-02
WO1995027061A1 (en) 1995-10-12
JPH09511644A (ja) 1997-11-25
EP0804572A1 (de) 1997-11-05
EP2067790A2 (de) 2009-06-10
CA2185656A1 (en) 1995-10-12
ATE489402T1 (de) 2010-12-15
JP2005218452A (ja) 2005-08-18
HK1131791A1 (en) 2010-02-05
PT2067790E (pt) 2012-01-11

Similar Documents

Publication Publication Date Title
ATE527357T1 (de) Agonistischer antikörper gegen proteintyrosinkinase sal-s1
DE69926536D1 (de) Antagonisten von vaskular-endothelialen zellwachstumsfaktoren und ihre anwendung
CY1107821T1 (el) Πολυπεπτιδιο παραγοντα viii με ενεργοτητα παραγοντα viii:c
ATE247667T1 (de) Gdnf-rezeptor und dessen verwendung
DK0848755T3 (da) VEGF relateret protein
NO20000934D0 (no) Adipocyttspesifikke proteinhomologer
BR0012569A (pt) Proteìnas de fusão fc para aumentar a imunogenicidade de antìgenos de peptìdeo e proteìna
DK0584082T3 (da) Domæner i den ekstracellulære region af humane blodpladeafledte vækstfaktorreceptorpolypeptider
NZ330897A (en) Human trk receptors and neurotropic factor inhibitors
DK0686161T3 (da) Alfa-underenhed af humane beta2-integriner
IL100343A0 (en) G protein coupled glutamate receptors
DE69126607D1 (de) Extrazelluläre teilstücke humaner ige-immunoglobulin-ankerpeptide und dafür spezifische antikörper
DK1002075T3 (da) Adipocyt-specifikke proteinhomologer
EP0854185A3 (de) Rezeptor-Proteine zu Bestimmungszwecke und Liganden
DK1447414T3 (da) Antagonistpeptider af carcinoembronisk antigen (CEA)
ATE132162T1 (de) Humane gammainterferonantagonisten
PT723552E (pt) Oligopeptidos derivados de fragmentos de proteina reactiva c
AU4661293A (en) Peptides representing antigenic epitopes of ige present on b cell but not basophil surface
CA2218755A1 (en) Monoclonal antibody to human beta 2 integrin alpha subunit
SE9601231D0 (sv) Monoclonal antibody
RU94026276A (ru) Рецепторы интерлейкина-12 и антител
WO1998050425A3 (en) Human tsc-22-like proteins

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2067790

Country of ref document: EP